3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Brain Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pain, Postoperative
2
Pain
2
Ovarian Neoplasms
2
Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
6
avelumab
6
Nivolumab
5
Specimen Handling
4
Magnetic Resonance Spectroscopy
3
Biopsy
3
prednylidene
2
lutetium Lu 177 dotatate
2
deltacortene
2
Prednisone
2
Ipilimumab
2
CTLA-4 Antigen
2
talimogene laherparepvec
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
aldesleukin
1
Tacrolimus
1
Sirolimus
1
Saline Solution
1
Radiotherapy
1
Radiosurgery
1
MAPRE1 protein, human
1
Lutetium-177
1
Laparoscopy
1
Exercise Test
1
Cyclophosphamide
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
Saline Solution
×
90 days
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled